SCHEDULE: Nantahala Capital Management Boosts Immunic Stake

Nantahala Capital Management, LLC, along with its managing members, has disclosed beneficial ownership of 7.47% of Immunic, Inc.'s common stock as of June 30, 2026.

Summary

• Nantahala Capital Management, LLC, and its managing members Wilmot B. Harkey and Daniel Mack, have filed a Schedule 13G, indicating their beneficial ownership of Immunic, Inc. common stock.
• As of June 30, 2026, the reporting persons collectively beneficially own 1,079,843 shares, representing 7.47% of the class of securities.
• This ownership includes 829,197 shares that can be acquired within sixty days through the exercise of convertible securities.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not overwhelming stake acquisition by an investment manager. The lack of specific forward-looking statements or operational updates tempers a more enthusiastic assessment.

Positives

• Nantahala Capital Management, LLC, along with its managing members, has established a significant beneficial ownership stake of 7.47% in Immunic, Inc.
• The reporting persons have the ability to acquire an additional 829,197 shares through convertible securities, indicating potential for increased influence or investment.
• The filing confirms that the shares were acquired and are held in the ordinary course of business, suggesting a standard investment strategy rather than a hostile takeover attempt.

Negatives

• The filing does not provide specific details on the cost basis or the exact timing of the acquisition of these shares.
• There is no information regarding the specific convertible securities held or their terms.

Risks

• The acquisition of a substantial stake, even if in the ordinary course of business, could be interpreted by some as a precursor to seeking greater influence or control, which might be viewed negatively by current management or other shareholders.
• The reliance on convertible securities introduces a degree of uncertainty regarding the final ownership percentage and the timing of its realization.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company. The future outlook is primarily shaped by the reporting persons' intent to hold securities in the ordinary course of business and their ability to acquire additional shares via convertible securities.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment management firms, as reported in Schedule 13G filings, are common in the biotechnology and pharmaceutical sectors. These filings often signal increased investor interest or a strategic shift in holdings, which can be closely watched by the market.

Stakeholder Impact

• Shareholders: The acquisition of a significant stake by Nantahala Capital Management may influence market perception and potentially lead to increased trading volume or scrutiny of Immunic, Inc.'s performance.
• Management: The increased ownership by an investment manager could lead to closer monitoring of company strategy and performance by the reporting persons.

Next Steps

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack will continue to hold their beneficial ownership of Immunic, Inc. shares.
• The reporting persons may acquire additional shares through the exercise of convertible securities within the next sixty days.

Key Dates

Keywords

Immunic, Nantahala Capital Management, Schedule 13G, Beneficial Ownership, Investment Management, Convertible Securities, Shareholder